• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

微生物组：影响癌症治疗结果的新变量。

The Microbiota: A New Variable Impacting Cancer Treatment Outcomes.

机构信息

Department of Pathology, University of Chicago, Chicago, Illinois.

Department of Medicine, University of Chicago, Chicago, Illinois.

出版信息

Clin Cancer Res. 2017 Jul 1;23(13):3229-3231. doi: 10.1158/1078-0432.CCR-17-0864. Epub 2017 Apr 26.

DOI:10.1158/1078-0432.CCR-17-0864
PMID:28446507
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5627769/
Abstract

Preclinical evidence has established that the host commensal microbiota can contribute to therapeutic response in cancer models, a finding supported by early clinical data. This connection between the microbiome and clinical outcome in oncology is cause for new consideration in the administration of antibiotics and microbiota-modulating interventions to improve outcomes. .

摘要

临床前证据已经确立，宿主共生微生物组可以促进癌症模型中的治疗反应，这一发现得到了早期临床数据的支持。这种微生物组与肿瘤学临床结果之间的联系，促使人们重新考虑使用抗生素和调节微生物组的干预措施来改善治疗效果。

相似文献

1
The Microbiota: A New Variable Impacting Cancer Treatment Outcomes.微生物组：影响癌症治疗结果的新变量。
Clin Cancer Res. 2017 Jul 1;23(13):3229-3231. doi: 10.1158/1078-0432.CCR-17-0864. Epub 2017 Apr 26.
2
Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient?考虑微生物组能否改善肿瘤患者的抗菌药物利用和治疗结果？
Clin Cancer Res. 2017 Jul 1;23(13):3263-3268. doi: 10.1158/1078-0432.CCR-16-3173. Epub 2017 Mar 15.
3
A case for antibiotic perturbation of the microbiota leading to allergy development.一个关于抗生素扰动微生物群导致过敏发展的案例。
Expert Rev Clin Immunol. 2013 Nov;9(11):1019-30. doi: 10.1586/1744666X.2013.851603.
4
Oncologists tap the microbiome in bid to improve immunotherapy outcomes.肿瘤学家利用微生物群来改善免疫治疗效果。
Nat Rev Drug Discov. 2018 Mar;17(3):153-155. doi: 10.1038/nrd.2018.19. Epub 2018 Feb 16.
5
Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome.肠道微生物群的改变是肠易激综合征的病因及一种潜在的治疗选择。
Benef Microbes. 2014 Sep;5(3):247-61. doi: 10.3920/BM2013.0033.
6
Initial Gut Microbial Composition as a Key Factor Driving Host Response to Antibiotic Treatment, as Exemplified by the Presence or Absence of Commensal Escherichia coli.初始肠道微生物组成作为驱动宿主对抗生素治疗反应的关键因素，以共生大肠杆菌的存在与否为例。
Appl Environ Microbiol. 2017 Aug 17;83(17). doi: 10.1128/AEM.01107-17. Print 2017 Sep 1.
7
Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?炎症性肠病能否通过对微生物群的短期干预得到根治？
Expert Rev Gastroenterol Hepatol. 2015 Jun;9(6):781-95. doi: 10.1586/17474124.2015.1013031. Epub 2015 Feb 10.
8
Human microbiota and effectiveness of cancer chemotherapy.人类微生物群与癌症化疗的疗效。
Exp Oncol. 2020 Jun;42(2):82-93. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-2.14611.
9
[The intestinal microbiota: a boost for antitumor treatments].[肠道微生物群：抗肿瘤治疗的助力]
Med Sci (Paris). 2014 Apr;30(4):436-8. doi: 10.1051/medsci/20143004019. Epub 2014 May 5.
10
Stress and antibiotics alter luminal and wall-adhered microbiota and enhance the local expression of visceral sensory-related systems in mice.应激和抗生素会改变腔和壁附着的微生物群，并增强小鼠内脏感觉相关系统的局部表达。
Neurogastroenterol Motil. 2013 Aug;25(8):e515-29. doi: 10.1111/nmo.12154. Epub 2013 May 27.

引用本文的文献

1
Elevated HDAC4 Expression Is Associated with Reduced T-Cell Inflamed Tumor Microenvironment Gene Signatures and Immune Checkpoint Inhibitor Effectiveness in Melanoma.组蛋白去乙酰化酶4（HDAC4）表达升高与黑色素瘤中T细胞炎症性肿瘤微环境基因特征的降低及免疫检查点抑制剂疗效相关。
Cancers (Basel). 2025 Apr 30;17(9):1518. doi: 10.3390/cancers17091518.
2
From microbes to medicine: harnessing the gut microbiota to combat prostate cancer.从微生物到医学：利用肠道微生物群对抗前列腺癌。
Microb Cell. 2024 May 23;11:187-197. doi: 10.15698/mic2024.05.824. eCollection 2024.
3
Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer.抗生素的使用降低了晚期黑色素瘤和非小细胞肺癌患者酪氨酸激酶抑制剂的疗效。
ESMO Open. 2022 Jun;7(3):100430. doi: 10.1016/j.esmoop.2022.100430. Epub 2022 Apr 27.
4
Investigating efficacy of "microbiota modulation of the gut-lung Axis" combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial.探讨“肠道-肺部轴的微生物群调节”联合化疗治疗晚期 NSCLC 患者的疗效：一项多中心、前瞻性、双盲、安慰剂对照、随机试验的研究方案。
BMC Cancer. 2021 Jun 22;21(1):721. doi: 10.1186/s12885-021-08448-6.
5
Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy.微生物群与肺癌。提高免疫治疗疗效的机遇与挑战。
Front Oncol. 2020 Sep 24;10:568939. doi: 10.3389/fonc.2020.568939. eCollection 2020.
6
Why the Outcome of Anti-Tumor Immune Responses is Heterogeneous: A Novel Idea in the Context of Immunological Heterogeneity in Cancers.为什么抗肿瘤免疫反应的结果具有异质性：癌症中免疫学异质性背景下的一个新观点。
Bioessays. 2020 Oct;42(10):e2000024. doi: 10.1002/bies.202000024. Epub 2020 Aug 7.
7
The effects of growth hormone on therapy resistance in cancer.生长激素对癌症治疗耐药性的影响。
Cancer Drug Resist. 2019 Summer;2(3):827-846. doi: 10.20517/cdr.2019.27. Epub 2019 Sep 19.
8
Biomineralized Bimetallic Oxide Nanotheranostics for Multimodal Imaging-Guided Combination Therapy.用于多模态成像引导联合治疗的生物矿化双金属氧化物纳米诊疗剂。
Theranostics. 2020 Jan 1;10(2):841-855. doi: 10.7150/thno.40715. eCollection 2020.
9
Temperature as a modulator of the gut microbiome: what are the implications and opportunities for thermal medicine?温度作为肠道微生物组的调节剂：热医学的意义和机遇是什么？
Int J Hyperthermia. 2019 Nov;36(sup1):83-89. doi: 10.1080/02656736.2019.1647356.
10
The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies.肠道微生物群与免疫检查点抑制剂反应：临床前和临床策略
Clin Transl Med. 2019 Mar 18;8(1):9. doi: 10.1186/s40169-019-0225-x.

本文引用的文献

1
Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient?考虑微生物组能否改善肿瘤患者的抗菌药物利用和治疗结果？
Clin Cancer Res. 2017 Jul 1;23(13):3263-3268. doi: 10.1158/1078-0432.CCR-16-3173. Epub 2017 Mar 15.
2
Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota.抗肿瘤治疗的疗效与使用调节肠道微生物群的抗生素有关。
Oncoimmunology. 2016 Apr 22;5(6):e1150399. doi: 10.1080/2162402X.2016.1150399. eCollection 2016 Jun.
3
Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.在人类患者和小鼠接受异基因造血干细胞移植后，使用广谱抗生素会增加移植物抗宿主病（GVHD）相关死亡率。
Sci Transl Med. 2016 May 18;8(339):339ra71. doi: 10.1126/scitranslmed.aaf2311.
4
Microbiome mediation of infections in the cancer setting.微生物群在癌症环境中对感染的介导作用。
Genome Med. 2016 Apr 18;8(1):40. doi: 10.1186/s13073-016-0306-z.
5
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.肠道微生物组分析可识别出有发生检查点阻断诱导性结肠炎风险的黑色素瘤患者。
Nat Commun. 2016 Feb 2;7:10391. doi: 10.1038/ncomms10391.
6
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.通过CTLA-4阻断进行的抗癌免疫疗法依赖于肠道微生物群。
Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.
7
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.共生双歧杆菌可促进抗肿瘤免疫并增强抗程序性死亡受体配体1（PD-L1）的疗效。
Science. 2015 Nov 27;350(6264):1084-9. doi: 10.1126/science.aac4255. Epub 2015 Nov 5.
8
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.肠道微生物群调节环磷酰胺的抗癌免疫作用。
Science. 2013 Nov 22;342(6161):971-6. doi: 10.1126/science.1240537.
9
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.共生菌通过调节肿瘤微环境来控制癌症对治疗的反应。
Science. 2013 Nov 22;342(6161):967-70. doi: 10.1126/science.1240527.
10
Role of the gut microbiota in immunity and inflammatory disease.肠道微生物群在免疫和炎症性疾病中的作用。
Nat Rev Immunol. 2013 May;13(5):321-35. doi: 10.1038/nri3430.